BIO-TECHNE CORP's ticker is TECH and the CUSIP is 09073M104. A total of 546 filers reported holding BIO-TECHNE CORP in Q1 2023. The put-call ratio across all filers is 0.40 and the average weighting 0.2%.
About BIO-TECHNE CORP
Bio-Techne Corp is a leading provider of innovative life science research tools and diagnostic solutions. The company is headquartered in Minneapolis, Minnesota, and has operations in over 50 countries worldwide. Bio-Techne's products and services are used by researchers and clinicians in a wide range of fields, including cancer research, stem cell research, and immunology.
Bio-Techne's success is due in large part to its commitment to innovation and customer service. The company invests heavily in research and development, and has a team of over 1,000 scientists working to develop new products and technologies. Bio-Techne also has a strong focus on customer service, with a dedicated team of technical support specialists available to assist customers with any questions or issues they may have.
In addition to its research tools and diagnostic solutions, Bio-Techne also has a growing portfolio of clinical diagnostic products. The company's Exosome Diagnostics subsidiary is a leader in the development of liquid biopsy tests for cancer diagnosis and monitoring.
Bio-Techne's leadership team is comprised of experienced executives with a track record of success in the life sciences industry. Charles Kummeth, the company's CEO, has been with Bio-Techne since 2013 and has overseen significant growth and expansion during his tenure.
Overall, Bio-Techne is a company with a strong reputation for innovation, customer service, and leadership in the life sciences industry. With a growing portfolio of products and services, the company is well-positioned for continued success in the years to come.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2024 | $1,227,579 | +7.6% | 17,133 | +5.7% | 0.01% | +25.0% |
Q1 2024 | $1,141,233 | -8.1% | 16,213 | +0.7% | 0.00% | -20.0% |
Q4 2023 | $1,242,122 | +11.1% | 16,098 | -2.0% | 0.01% | -28.6% |
Q3 2023 | $1,118,118 | -10.4% | 16,426 | +7.5% | 0.01% | 0.0% |
Q2 2023 | $1,247,388 | +19.3% | 15,281 | +8.5% | 0.01% | 0.0% |
Q1 2023 | $1,045,337 | -6.6% | 14,090 | +4.4% | 0.01% | -22.2% |
Q4 2022 | $1,118,714 | +86.1% | 13,498 | +538.2% | 0.01% | +50.0% |
Q3 2022 | $601,000 | +82.1% | 2,115 | +122.2% | 0.01% | +100.0% |
Q2 2022 | $330,000 | -69.4% | 952 | -61.7% | 0.00% | -50.0% |
Q1 2022 | $1,077,000 | -26.2% | 2,486 | -11.8% | 0.01% | -25.0% |
Q4 2021 | $1,459,000 | +142.8% | 2,820 | +127.4% | 0.01% | +100.0% |
Q3 2021 | $601,000 | – | 1,240 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Blue Water Life Science Advisors, LP | 54,711 | $28,304,000 | 8.66% |
Montanaro Asset Management Ltd | 104,450 | $54,036,000 | 5.45% |
Ownership Capital B.V. | 891,186 | $461,046,000 | 4.99% |
Sandhill Capital Partners LLC | 121,682 | $62,951,000 | 4.89% |
Brown Capital Management | 986,803 | $510,513,000 | 4.22% |
STONE RUN CAPITAL, LLC | 22,300 | $11,536,000 | 3.73% |
DF DENT & CO INC | 681,416 | $352,524,000 | 3.54% |
MAIRS & POWER INC | 653,815 | $338,244,000 | 3.13% |
Summit Creek Advisors LLC | 57,959 | $29,985,000 | 3.01% |
Aristotle Atlantic Partners, LLC | 95,597 | $49,456,000 | 2.87% |